Cellectis S.A.

Cellectis is a France-based biotechnology developer working on gene-edited cell therapies, including engineered T-cell approaches for cancer treatment. The company applies gene-editing technologies to develop therapeutic products and collaborates with partners in advancing these platforms. Its investor FAQ identifies ordinary shares on Euronext Growth Paris under ALCLS and American-listed securities on Nasdaq under CLLS, representing the same issuer across markets. A brief identity and technology overview is retained here, while clinical-program timing and partnership economics are left to its official investor and pipeline pages.